Tekrardan Hoşgeldiniz
Cointime’a Katıl
Giriş Yap
Kayıt Ol
Gelen kutunuzu kontrol edin
Athenex
About
Athenex is a biopharmaceutical company that develops and discovers novel therapies for treating cancer and related conditions.
- Buffalo,New York,United States
- 251 - 500
- http://www.athenex.com
Details
- Last Funding Type
- Post-IPO Equity
- Last Funding Money Raised
- $30M
- Industries
- Biotechnology,Medical,Pharmaceutical
- Founded date
- Jan 1, 2003
- Number Of Employee
- 251 - 500
- Operating Status
- Active
- Stock Symbol
- nasdaq:ATNX
- Legal Name
- Athenex, Inc.
- Also Known As
- Kinex Pharmaceuticals
Athenex focuses on the development and commercialization of therapies for cancer and immunomodulatory diseases. Its mission is to become a global leader in bringing innovative cancer treatments to the market and improve health outcomes. The company was founded in 2003 in Buffalo, New York, and has since grown to have operations across the U.S., China, Hong Kong, Taiwan, and the U.K.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Aug 11, 2022 | Post-IPO Equity | $30M | — | — | — | Detail |
| Dec 5, 2019 | Post-IPO Equity | $60M | 1 |
Kingdon Capital
|
— | Detail |
| May 6, 2019 | Post-IPO Equity | $100M | 2 | — | — | Detail |
| Jul 2, 2018 | Post-IPO Equity | $50M | 1 |
Perceptive Advisors
|
— | Detail |
| Jun 14, 2017 | IPO | $66M | — | — | — | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Kingdon Capital
|
Yes | Post-IPO Equity |
OrbiMed
|
— | Post-IPO Equity |
|
Perceptive Advisors
|
— | Post-IPO Equity |
Mandra Capital
|
— | Private Equity（PE） |
Employee Profiles
Acquisition
Athenex has acquired 3 organizations. Their most recent acquisition was QuaDPharma on Sep 9, 2014. They acquired QuaDPharma for 0.
|
Date
Company Name
|
Industry | Acquisition Type | Price | |
|---|---|---|---|---|
|
Sep 9, 2014
QuaDPharma
|
Biopharma | acquisition | — | Detail |
|
Dec 14, 2015
|
Pharmaceutical | acquisition | — | Detail |
|
May 4, 2021
Kuur Therapeutics
|
Biotechnology | acquisition | $ 185M | Detail |
